Hydrolysis of 4-acetoxystyrene polymers prepared by atom transfer radical polymerization

Lignin phenolation by graft copolymerization to boost its reactivity

Lignin is the most abundant phenolic biopolymer and a renewable resource of aromatics. It can be used as a phenol substitute in the synthesis of phenolic resins. However, lignin is not as reactive as phenol, so phenolation is generally carried out to improve lignin reactivity. In this work, we suggest a solution to circumvent the limitations of traditional phenolation (e.g., high temperature, strong acids/bases, limited reactivity, and phenol toxicity). We first attempt new lignin phenolation by graft copolymerization in which polymeric phenol, instead of toxic phenol, is introduced to lignin. Organosolv lignin from hardwood was modified with 2-bromoisobutyryl bromide to act as a lignin macroinitiator (L-Br). A protected phenolic monomer, 4-acetoxystyrene, was graft copolymerized onto L-Br using CuBr2/tris[2-(dimethylamino)ethyl]amine as a catalyst/ligand, after which the resultant lignin copolymer was deacetylated to produce lignin grafted with poly(4-hydroxystyrene). This poly-phenolation process was conducted at room temperature without the strong acids/bases and toxic phenol required in conventional phenolation. The poly-phenolated lignin was analyzed using 1H-, 13C-, and 31P NMR spectroscopy and gel permeation chromatography. This novel phenolation process enhanced the reactive sites of lignin more than tenfold. It also reduced the dark color of technical lignins significantly, thereby overcoming a serious obstacle to their applicability.

Controlled Delivery of Paclitaxel from Stent Coatings Using Poly(hydroxystyrene-b-isobutylene-b-hydroxystyrene) and Its Acetylated Derivative

A poly(styrene-b-isobutylene-b-styrene) (SIBS) triblock polymer is employed as the polymer drug carrier for the TAXUS Express2 Paclitaxel-Eluting Coronary Stent system (Boston Scientific Corp.). It has been shown that the release of paclitaxel (PTx) from SIBS can be modulated by modification of either drug-loading ratio or altering the triblock morphology by blending. In the present work, results toward achieving release modulation of PTx by chemical modification of the styrenic portion (using hydroxystyrene or its acetylated version) of the SIBS polymer system are reported. The synthesis of the precursor poly[(p-tert-butyldimethylsilyloxystyrene)]-b-isobutylene-b-[(p-tert-butyldimethylsilyloxystyrene] triblock copolymers was accomplished by living sequential block copolymerization of isobutylene (IB) and p-(tert-butyldimethylsiloxy)styrene (TBDMS) utilizing the capping-tuning technique in a one-pot procedure in methylcyclohexane/CH3Cl at -80 degrees C. This procedure involved the living cationic polymerization of IB with the 5-tert-butyl-1,3-bis(1-chloro-1-methylethyl)benzene/TiCl4 initiating system and capping of living difunctional polyisobutylene (PIB) chain ends with 1,1-ditolylethylene (DTE) followed by addition of titanium(IV) isopropoxide (Ti(OIp)4) to lower the Lewis acidity before the introduction of TBDMS. Deprotection of the product with tetrabutylammonium fluoride yielded poly(hydroxystyrene-b-isobutylene-b-hydroxystyrene), which was quantitatively acetylated to obtain the acetylated derivative. The hydroxystyrene and acetoxystyrene triblock copolymers have acceptable mechanical properties for use as drug delivery coatings for coronary stent applications. It was concluded that the hydrophilic nature of the endblocks and polarity effects on the drug/polymer miscibility lead to enhanced release of PTx from these polymers. The drug-polymer miscibility was confirmed by differential scanning calorimetry and atomic force microscopy evaluations.